DHR
HealthcareDanaher Corporation
$235.36
+$4.96 (+2.15%)
Jan 5, 2026
Price History (1Y)
Analysis
Danaher Corporation is a multinational company operating within the healthcare sector, specifically in the diagnostics and research industry. With a market capitalization of $168.53 billion, it ranks among large-cap companies, boasting a substantial revenue stream of $24.27 billion (TTM) and employing approximately 61,000 individuals. The company's financial health is notable, with operating margins standing at 20.8% and profit margins reaching 14.4%. Return on equity (ROE) and return on assets (ROA) are 6.8% and 4.1%, respectively, indicating moderate profitability levels. The balance sheet shows $18.16 billion in debt and $1.53 billion in cash, resulting in a debt-to-equity ratio of 35.54. Danaher Corporation's valuation metrics include a price-to-earnings (P/E) ratio of 47.36 (TTM), which is high compared to some industry standards. Forward P/E stands at 27.95, indicating a decrease from the trailing twelve months' P/E ratio. Revenue growth has been steady, with an annual increase of 4.4%, while earnings growth has accelerated to 13.4%. The dividend yield is 56.0%, with a payout ratio of 25.3%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
Visit website →Key Statistics
- Market Cap
- $168.53B
- P/E Ratio
- 47.36
- 52-Week High
- $258.23
- 52-Week Low
- $171.00
- Avg Volume
- 3.60M
- Beta
- 0.93
- Dividend Yield
- 56.00%
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NYQ
- Country
- United States
- Employees
- 61,000